EXHIBIT 12.1

	Ratio of Earnings to Fixed Charges
	(dollars in thousands, except ratio data)
	March 31,			December 31,			December 31,			December 31,			December 31,			December 31,
	2005			2004			2003			2002			2001			2000
Fixed Charges:
Interest expense on indebtedness (including amortization of debt expense and discount)	$	4,707		$	22,868		$	23,723		$	23,746		$	24,638		$	22,088
Interest expense on portion of rent expense representative of interest		3,265			9,089			7,604			7,206			6,159			3,251
Total Fixed Charges	$	7,972		$	31,957		$	31,327		$	30,952		$	30,797		$	25,339
Earnings (Loss):
Net loss before provision for income taxes and cumulative effect of change in accounting principle	$	(59,582	)	$	(242,898	)	$	(185,324	)	$	(219,716	)	$	(117,152	)	$	(235,331	)
Fixed Charges per above		7,972			31,957			31,327			30,952			30,797			25,339
Total Earnings (Loss)	$	(51,610	)	$	(210,941	)	$	(153,997	)	$	(188,764	)	$	(86,355	)	$	(209,992	)
Ratio of Earnings to Fixed Charges		—			—			—			—			—			—
Coverage deficiency(1)(2)(3)(4)	$	(59,582	)	$	(242,898	)	$	(185,324	)	$	(219,716	)	$	(117,152	)	$	(235,331	)

(1)	The Company’s Coverage deficiency for 2004 includes net charges of $12,975, relating to a $15,408 charge for restructuring partially offset by a gain recognized on the extinguishment of debt of $2,433.
(2)	The Company’s Coverage deficiency for 2002 includes charges aggregating $46,396 arising from the Company’s impairment charge relating to its investment in CAT and a charge for construction design changes of $32,158 and $14,238, respectively.
(3)	The Company’s Coverage deficiency for 2001 includes charges aggregating $26,208 arising from the Company’s impairment charge relating to its investment in Transgene and debt conversion expenses of $22,314 and $3,894, respectively.
(4)	The Company’s Coverage deficiency for 2000 includes charges aggregating $184,868 arising from purchased in-process research and development and debt conversion expenses of $134,050 and $50,818, respectively.